Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Immatics NV (NQ: IMTX ) 9.330 +0.230 (+2.53%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Immatics NV < Previous 1 2 3 Next > Immatics Announces Pricing of $150 Million Public Offering October 10, 2024 From https://immatics.com/ Via GlobeNewswire Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday? October 10, 2024 Immatics announced updated Phase 1b data for its IMA203 therapy in metastatic melanoma. A deep tumor reduction response was observed in about half of the patients, with positive survival benefits... Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session October 10, 2024 Via Benzinga Immatics Announces Proposed $150 Million Public Offering October 10, 2024 From https://immatics.com/ Via GlobeNewswire Why Immatics Shares Are Rising Today July 24, 2023 Immatics N.V. (NASDAQ: IMTX) shares are trading higher after the company announced Via Benzinga Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial October 10, 2024 From https://immatics.com/ Via GlobeNewswire Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024 October 04, 2024 From https://immatics.com/ Via GlobeNewswire Biotech Stocks : Are You A Trader Or A Longer Term Investor? October 01, 2024 Biotech bull market is intact as indicated by large cap biopharma and the best performing funds. Via Talk Markets Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update September 16, 2024 From https://immatics.com/ Via GlobeNewswire Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024 September 06, 2024 From https://immatics.com/ Via GlobeNewswire IMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q2 2024 August 13, 2024 IMTX stock results show that Immatics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. Via InvestorPlace Immatics Announces Second Quarter 2024 Financial Results and Business Update August 13, 2024 From https://immatics.com/ Via GlobeNewswire Immatics Appoints Alise Reicin to Board of Directors July 31, 2024 From https://immatics.com/ Via GlobeNewswire Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024 July 18, 2024 From https://immatics.com/ Via GlobeNewswire Trading SMID Biotech Stocks In A Volatile Market July 01, 2024 Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... Via Talk Markets 12 Health Care Stocks Moving In Friday's Intraday Session May 24, 2024 Via Benzinga Immatics Announces First Quarter 2024 Financial Results and Business Update May 14, 2024 From https://immatics.com/ Via GlobeNewswire IMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q4 2023 March 21, 2024 IMTX stock results show that Immatics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. Via InvestorPlace 12 Health Care Stocks Moving In Thursday's Pre-Market Session March 21, 2024 Via Benzinga Immatics Announces Full Year 2023 Financial Results and Corporate Update March 21, 2024 From https://immatics.com/ Via GlobeNewswire 10 Health Care Stocks Whale Activity In Today's Session March 18, 2024 Via Benzinga Immatics Announces Pricing of $175 Million Public Offering January 17, 2024 From https://immatics.com/ Via GlobeNewswire Immatics Announces Proposed Public Offering January 17, 2024 From https://immatics.com/ Via GlobeNewswire Immatics Announces Third Quarter 2023 Financial Results and Business Update November 14, 2023 From https://immatics.com/ Via GlobeNewswire Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial November 08, 2023 From https://immatics.com/ Via GlobeNewswire Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy October 24, 2023 From https://immatics.com/ Via GlobeNewswire Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics September 11, 2023 Via ACCESSWIRE Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics September 11, 2023 From https://immatics.com/ Via GlobeNewswire Immatics Announces Second Quarter 2023 Financial Results and Business Update August 17, 2023 From https://immatics.com/ Via GlobeNewswire Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors August 10, 2023 From https://immatics.com/ Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
